SG/CALL/ELI LILLY & CO/950/0.1/17.01.25 | Real-time Bid/Ask 13:50:51 2024-05-10 EDT | ||
| 2.86 EUR / 2.91 EUR | -9.56% |
|
| Current month | +25.59% | ||
| 1 month | -23.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 3.05 | -4.39% | 0 |
| 24-05-09 | 3.19 | -2.15% | 0 |
| 24-05-08 | 3.26 | +17.27% | 0 |
| 24-05-07 | 2.78 | +25.23% | 0 |
| 24-05-06 | 2.22 | -12.60% | 0 |
Delayed Quote Börse Stuttgart
Last update May 10, 2024 at 03:21 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU92YG |
| ISIN | DE000SU92YG9 |
| Date issued | 2024-02-29 |
| Strike | 950 $ |
| Maturity | 2025-01-17 (252 Days) |
| Parity | 10 : 1 |
| Emission price | 3.89 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.11 € |
|---|---|
| Lowest since issue | 2.22 € |
| Spread | 0.05 € |
| Spread % | 1.73% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
771.6
USD
Average target price
850.4
USD
Spread / Average Target
+10.22%
- Stock Market
- Warrants
- Warrant